33 reports

  • Description and impact on the market
  • 13.3 Factors that impede market growth

Thus, there is a high demand for lipid-lowering drugs with a good safety profile.

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • INDUSTRY HIGHLIGHTS
  • GLOBAL HYPERCHOLESTEROLEMIA DRUGS MARKET 2015-2020 ($ BILLIONS)
  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • ST-103 - Drug Profile
  • Lipid Modifying Drug
  • United States
  • World
  • Product Initiative
  • Gemphire Therapeutics Inc.
  • ITALY ACS MARKET - DRIVERS AND BARRIERS, 2015-2025
  • 2.1 CATALYST

THUS, IT WILL NOT BE DIRECTLY COMPETING WITH THE SOC LIPID-LOWERING DRUGS.

  • Lipid Modifying Drug
  • World
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • R&D Progress
  • SMALL MOLECULE TO ANTAGONIZE FARNESOID X RECEPTOR FOR DYSLIPIDEMIA - DRUG PROFILE

ROSUVASTATIN IS AN ANTILIPIDEMIC AGENT THAT COMPETITIVELY INHIBITS HYDROXYMETHYLGLUTARYL-COENZYME A (HMG-COA) REDUCTASE.

  • Cholesterol
  • Chronic Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • Esperion Therapeutics, Inc.
  • EVOLOCUMAB - DRUG PROFILE
  • Other Developmental Activities

The Phase III ##-week, double-blind, randomized, placebo-controlled, multicenter part of the TESLA trial evaluated evolocumab in ## patients with HoFH (LDL-C ## mg/ dL) who were on a stable dose of statin therapy and lipid-lowering medication.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative
  • EVOLOCUMAB - DRUG PROFILE
  • Mixed Dyslipidemia - Recent Pipeline Updates

Phase III - Trial Details EVOLOCUMAB - DRUG PROFILE Product Description Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.
  • 5. All the trials included are unique trials.

Lipid-lowering Drugs in Japanese Subjects with Hypercholesterolemia (Study P##) GDCT## NCT##, P## Metabolic Disorders Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), Hypercholesterolemia (Low Density Lipoprotein (LDL)) Completed Phase IV Observational ezetimib

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Cardiovascular Disease
  • Clinical Trial
  • Endocrine Disease
  • Lipid Modifying Drug
  • AstraZeneca PLC

NEW ERA OF LIPID-LOWERING DRUGS.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Lipid Modifying Medication(S) in Patients with Heterozygous Familial Hypercholesterolemia Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered with Statin in Participants with Heterozygous Familial Hypercholesterolemia (MK-##-##) (REALIZE) GDCT## NCT##,

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Jul 28, 2011
  • Other Developmental Activities

Patients arriving at hospital with ACS (heart attacks) will receive CER-## infusions or placebo in addition to standard of care (including lipid lowering drugs such as statins).

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • R&D
  • United States
  • Product Initiative
  • Clinical Trial profile. 92 Trial Title
  • Clinical Trial Profile Snapshots

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Discovery And Development
  • Lipid Modifying Drug
  • World
  • HCP-1105 - DRUG PROFILE
  • SMALL MOLECULE TO ANTAGONIZE FARNESOID X RECEPTOR FOR DYSLIPIDEMIA - DRUG PROFILE

Results also showed increased benefits after ## weeks of treatment, with patients on a daily dose of ##g of CaPre, registering a mean triglyceride decrease of ##. ##% and an absolute mean improvement of ##. ##% as compared to Standard of Care, in which, due to lipid lowering medication adjustment

  • Chronic Disease
  • Lipid Modifying Drug
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 105 Trial Title
  • Clinical Trial Profile Snapshots

Lipid-lowering Drugs in Japanese Subjects with Hypercholesterolemia (Study P##) GDCT## NCT##, P## Metabolic Disorders Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), Hypercholesterolemia (Low Density Lipoprotein (LDL)) Completed Phase IV Observational ezetimib

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Merck & Co., Inc.

lipid lowering drug University of Texas Health Science Center at Houston ## Mar 2009 ## Jan 2019 ## ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • BEZAFIBRATE ER - DRUG PROFILE
  • EVOLOCUMAB - DRUG PROFILE

Bezafibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Research and Development Brief
  • ST-103 - DRUG PROFILE

ROSUVASTATIN IS A STATIN WITH ANTILIPIDEMIC AND POTENTIAL ANTINEOPLASTIC ACTIVITIES.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • World
  • Product Initiative

lipid lowering drug University of Texas Health Science Center at Houston ## Mar 2009 ## Jan 2019 ## ## ## Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • ST-103 - DRUG PROFILE
  • (OLMESARTAN MEDOXOMIL + ROSUVASTATIN CALCIUM) - DRUG PROFILE

In November 2012, Merck initiated Phase III study to assess the efficacy and tolerability of anacetrapib when added to ongoing statin therapy with or without other lipid modifying medication(s) in patients with hypercholesterolemia or low HDL-C to evaluate the effects of ## different dose le

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • United States
  • Product Initiative

Lipid Modifying Medication(s) in Patients with Hypercholesterolemia or Low HDL-C A Study of the Safety and Efficacy of Anacetrapib (MK-##) When Added to Ongoing Statin Therapy (MK-##-##) GDCT## NCT##, ##-##; 2012-##-##; EudraCT- 2012-##-##; MK-##-## AM## Cardiovasc

  • Cardiovascular Disease
  • Chronic Disease
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • LEVELS (-49 TO -113 MG/DL) REPORTED FOR THE PHASE III FH CLINICAL TRIALS.
  • WEEK EFFICACY PHASE.

All of the patients were already taking a maximally tolerated dose of a statin, as well as additional lipid-lowering drugs in most cases.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 173 Trial Title

Niacin, Lipid Lowering Drug, was Less Used Due to Its Side Effects, Can Be Minimized by Adding Laropiprant.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Merck & Co., Inc.
  • EVOLOCUMAB - DRUG PROFILE
  • EVOLOCUMAB COMBINED GROUP WERE BACK PAIN, ARTHRALGIA, HEADACHE, MUSCLE SPASMS AND PAIN IN EXTREMITY.

The Phase III ##-week, double-blind, randomized, placebo-controlled, multicenter part of the TESLA trial evaluated evolocumab in ## patients with HoFH (LDL-C ## mg/ dL) who were on a stable dose of statin therapy and lipid-lowering medication.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • (OLMESARTAN MEDOXOMIL + ROSUVASTATIN CALCIUM) - DRUG PROFILE
  • Hypertension
  • Lipid Modifying Drug
  • Pharmaceutical
  • United States
  • Product Initiative

AS A RESULT, PHYSICIANS MAY EXPECT SIMILARLY STRINGENT STUDIES FOR NEW LIPID-MODIFYING DRUG THERAPIES.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

EFFECTIVENESS OF COMBINATION THERAPY WITH STATIN AND ANOTHER LIPID- MODIFYING AGENT COMPARED WITH INTENSIFIED STATIN MONOTHERAPY: A SYSTEMATIC REVIEW.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.